Department of Dermatology - Open Access Policy Deposits
Parent: School of Medicine
eScholarship stats: Breakdown by Item for May through August, 2026
| Item | Title | Total requests | Download | View-only | %Dnld |
|---|---|---|---|---|---|
| 3nk5r7mw | Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies | 604 | 550 | 54 | 91.1% |
| 3455571b | Amitriptyline-induced cutaneous hyperpigmentation: case report and review of psychotropic drug-associated mucocutaneous hyperpigmentation | 570 | 193 | 377 | 33.9% |
| 0zf2s1cf | Seborrheic Dermatitis: Exploring the Complex Interplay with Malassezia | 547 | 270 | 277 | 49.4% |
| 02k9z6qd | Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations | 453 | 120 | 333 | 26.5% |
| 5c88q182 | Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition | 402 | 116 | 286 | 28.9% |
| 44q8g6b8 | Update on the Management of Rosacea from the American Acne & Rosacea Society (AARS). | 392 | 297 | 95 | 75.8% |
| 1rd5q5tz | Triple Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% for Acne: Efficacy and Safety from a Pooled Phase 3 Analysis | 382 | 205 | 177 | 53.7% |
| 08j6337f | Staphylococcus epidermidis in the human skin microbiome mediates fermentation to inhibit the growth of Propionibacterium acnes: implications of probiotics in acne vulgaris | 337 | 131 | 206 | 38.9% |
| 2dn263n7 | Skin neurogenic inflammation | 328 | 114 | 214 | 34.8% |
| 8z66m3xd | Development of a human skin commensal microbe for bacteriotherapy of atopic dermatitis and use in a phase 1 randomized clinical trial | 316 | 76 | 240 | 24.1% |
| 6hz8s1mh | Eccrine chromhidrosis secondary to hyperbilirubinemia | 307 | 113 | 194 | 36.8% |
| 5r79d67k | Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus: report of a case and review of the literature | 282 | 72 | 210 | 25.5% |
| 5kk7h8hg | Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study | 259 | 79 | 180 | 30.5% |
| 69s5d7c2 | Short-Chain Fatty Acids from Cutibacterium acnes Activate Both a Canonical and Epigenetic Inflammatory Response in Human Sebocytes | 258 | 95 | 163 | 36.8% |
| 25j8m068 | Antimicrobial production by perifollicular dermal preadipocytes is essential to the pathophysiology of acne | 249 | 165 | 84 | 66.3% |
| 5fs883zh | Guidelines of care for the management of atopic dermatitis Section 2. Management and treatment of atopic dermatitis with topical therapies | 245 | 53 | 192 | 21.6% |
| 0793n5z2 | Isotretinoin therapy for the treatment of acne in patients with cystic fibrosis: a case series and review of the literature | 244 | 71 | 173 | 29.1% |
| 2vz565gs | Competition between skin antimicrobial peptides and commensal bacteria in type 2 inflammation enables survival of S. aureus | 238 | 104 | 134 | 43.7% |
| 47q8p2w7 | Nevoid melanoma and eruptive nevi from erlotinib | 235 | 80 | 155 | 34.0% |
| 76r5t591 | Guidelines of care for the management of atopic dermatitis Section 3. Management and treatment with phototherapy and systemic agents | 234 | 55 | 179 | 23.5% |
| 1rw3692c | Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis | 232 | 50 | 182 | 21.6% |
| 216788xg | Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study | 232 | 96 | 136 | 41.4% |
| 49f6450d | Host-microbiome interactions and recent progress into understanding the biology of acne vulgaris | 230 | 112 | 118 | 48.7% |
| 5xs3g48j | Acne and Rosacea | 230 | 90 | 140 | 39.1% |
| 0vp716bx | Pediatric chronic hand eczema: Epidemiology, clinical presentation, and management | 229 | 72 | 157 | 31.4% |
| 62d7n4g9 | Designing a broad-spectrum integrative approach for cancer prevention and treatment | 229 | 83 | 146 | 36.2% |
| 1h87c6v1 | S. aureus drives itch and scratch-induced skin damage through a V8 protease-PAR1 axis | 228 | 139 | 89 | 61.0% |
| 3m85j4j2 | DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth | 226 | 183 | 43 | 81.0% |
| 4mj865qb | Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel | 226 | 114 | 112 | 50.4% |
| 0g0537ph | Beneficial Effects of Early Pulsed Dye Laser Therapy in Individuals with Infantile Hemangiomas | 224 | 37 | 187 | 16.5% |
| 2qr3w771 | Urgent safety considerations for dermatologic surgeons in the COVID-19 pandemic | 223 | 61 | 162 | 27.4% |
| 47p4d8zv | Penicillamine-associated cutis laxa and milia en plaque - case report and review of cutaneous changes associated with penicillamine | 221 | 83 | 138 | 37.6% |
| 6t87g6qr | The Ubiquitous Human Skin Commensal Staphylococcus hominis Protects against Opportunistic Pathogens | 219 | 96 | 123 | 43.8% |
| 2800q59v | TREM2 macrophages induced by human lipids drive inflammation in acne lesions | 215 | 123 | 92 | 57.2% |
| 8p66q9fv | Pleomorphic dermal sarcoma in a man with HIV: report with next-generation sequencing analysis and review of the atypical fibroxanthoma/pleomorphic dermal sarcoma spectrum | 215 | 63 | 152 | 29.3% |
| 5sp112v7 | Managing Childhood and Adolescent Atopic Dermatitis in Primary Care: A US Expert Group Consensus | 214 | 121 | 93 | 56.5% |
| 9t16k3hw | Evaluation of stenoses using AI video models applied to coronary angiography | 211 | 83 | 128 | 39.3% |
| 1xf7w7x4 | Characteristics of research tracks in dermatology residency programs: a national survey | 206 | 83 | 123 | 40.3% |
| 25q9w6r9 | Dupilumab for bullous pemphigoid with intractable pruritus | 196 | 64 | 132 | 32.7% |
| 85m1b2b9 | The microbiome in patients with atopic dermatitis | 196 | 54 | 142 | 27.6% |
| 05j80943 | Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies | 194 | 103 | 91 | 53.1% |
| 0sg0z14s | Genitogluteal porokeratosis in an HIV-positive man: a case report and review of the literature on genital porokeratosis | 194 | 72 | 122 | 37.1% |
| 68c7v95d | Consensus Statement for the Management and Treatment of Port-Wine Birthmarks in Sturge-Weber Syndrome | 194 | 71 | 123 | 36.6% |
| 22t2148g | Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations | 193 | 97 | 96 | 50.3% |
| 55q795hc | Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis | 193 | 84 | 109 | 43.5% |
| 7bx0q1dh | Polygenic prediction of atopic dermatitis improves with atopic training and filaggrin factors | 192 | 120 | 72 | 62.5% |
| 3c12d713 | The Role of Sphingolipids and Sphingosine-1-phosphate—Sphingosine-1-phosphate-receptor Signaling in Psoriasis | 191 | 74 | 117 | 38.7% |
| 67t6b870 | Recommendations for rosacea diagnosis, classification and management: update from the global ROSacea COnsensus 2019 panel | 190 | 53 | 137 | 27.9% |
| 4pn6h3g6 | The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA‐AD™): a clinical outcome measure for the severity of atopic dermatitis | 189 | 34 | 155 | 18.0% |
| 7gn5j3gp | Incomplete human reference genomes can drive false sex biases and expose patient-identifying information in metagenomic data | 189 | 46 | 143 | 24.3% |
Note: Due to the evolving nature of web traffic, the data presented here should be considered approximate and subject to revision. Learn more.